(Hypertension. 1996;28:98-103.)
© 1996 American Heart Association, Inc.
Articles |
Departamento Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad de Malaga, and Hospital Regional Carlos Haya (P.A.-L.), Malaga, Spain.
In the present study, we studied angiotensin II type 1 (AT1) and type 2 (AT2) receptor messengers by quantitative reverse transcriptasepolymerase chain reaction. We examined peripheral blood mononuclear cells from 30 healthy subjects and 50 subjects with primary hypertension, in whom angiotensin Iconverting enzyme genotype was determined, before and after 15 days of treatment with different antihypertensive drugs. The medication included a calcium channel antagonist, an angiotensin Iconverting enzyme inhibitor, and a ß1-blocker. We also studied the relationship between AT1 receptor gene expression and biochemical parameters of the renin-angiotensin system. AT1 receptor messenger levels were positively correlated with plasma renin activity in both normotensive and untreated hypertensive subjects. Increases of this messenger and plasma angiotensin II levels were correlated with the D allele in the same individuals. AT1 receptor messenger levels decreased significantly with angiotensin Iconverting enzyme inhibitor treatment in subjects with the DD genotype, and a significant decrease was observed in subjects with the II and ID genotypes treated with a calcium antagonist. No changes were observed in mRNA with the ß1-blocker. We conclude that the AT2 receptor is not expressed in peripheral leukocytes and that AT1 receptor messenger levels vary in relation to angiotensin Iconverting enzyme genotype and pharmacological treatment. These results suggest that angiotensin Iconverting enzyme genotype may be an important factor when deciding on antihypertensive therapy in individuals with primary hypertension.
Key Words: receptors, angiotensin II angiotensin-converting enzyme antihypertensive therapy genotype polymerase chain reaction RNA
This article has been cited by other articles:
![]() |
H. J Milionis, M. S Kostapanos, K. Vakalis, I. Theodorou, I. Bouba, R. Kalaitzidis, I. Georgiou, M. S Elisaf, and K. C Siamopoulos Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 181 - 189. [Abstract] [PDF] |
||||
![]() |
B. Baudin Polymorphism in angiotensin II receptor genes and hypertension Exp Physiol, May 1, 2005; 90(3): 277 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jones, S. S. Dhamrait, J. R. Payne, E. Hawe, P. Li, I. S. Toor, L. Luong, P. T.E. Wootton, G. J. Miller, S. E. Humphries, et al. Genetic Variants of Angiotensin II Receptors and Cardiovascular Risk in Hypertension Hypertension, October 1, 2003; 42(4): 500 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, Y. Du, Y. Du, and X. Huang Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 25 - 30. [Abstract] [PDF] |
||||
![]() |
J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF] |
||||
![]() |
M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr Plasma brain natriuretic peptide concentration: impact of age and gender J. Am. Coll. Cardiol., September 4, 2002; 40(5): 976 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wang, A. Zagariya, O. Ibarra-Sunga, C. Gidea, E. Ang, S. Deshmukh, G. Chaudhary, J. Baraboutis, G. Filippatos, and B. D. Uhal Angiotensin II induces apoptosis in human and rat alveolar epithelial cells Am J Physiol Lung Cell Mol Physiol, May 1, 1999; 276(5): L885 - L889. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. I. Rice, C. A. Foy, and P. J. Grant Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease Cardiovasc Res, March 1, 1999; 41(3): 746 - 753. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |